Clinical Trials

Lymphoid

Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

CNS

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

NCT05472623 2025-09-15

Neo-Kan

Resectable Non-Small Cell Lung Cancer

NCT05717140 2025-08-07

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Melanoma

NCT03879811 2025-05-15

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

Colorectal Neoplasms

NCT04781855 2025-02-28

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05153304 2024-06-10

Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

Gastrointestinal Neoplasms, Neoplasms

NCT04361058 2023-12-05

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

MyeloidOther hematologic neoplasm

GATA2 Deficiency, Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05039736 2023-05-12

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05504642 2023-04-18

CERAD-IMMUNE

Gynecologic

Uterine Cervical Neoplasms, Lymphatic Metastasis

NCT04965714 2023-02-16

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

Resectable Hepatocellular Carcinoma

NCT05022394 2022-05-27

Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04044209 2022-01-20

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04430985 2021-10-27

IMMUNOX

Colorectal Neoplasms

NCT03390738 2021-05-03

Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Head & Neck

Nasopharyngeal Carcinoma

NCT04042506 2021-04-12

SBRT as a Vaccination for Metastatic Melanoma

Melanoma

NCT03576963 2021-04-05

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

Colorectal Neoplasms

NCT03920631 2021-03-23

MicroBLITZ

Lymphoid

Lymphoma, B-Cell

NCT03758729 2021-02-16

Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.

Melanoma

NCT04230330 2020-11-05

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04315155 2020-10-28

BENEFIT

Tumor-Agnostic

Adenocarcinoma

NCT04128020 2020-10-12

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03126461 2020-08-20

SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

Melanoma

NCT03014804 2020-07-24

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

CNSSarcoma

Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT03927248 2020-05-07

PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer

Genitourinary

Carcinoma, Renal Cell

NCT03768531 2020-04-13

Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

Biliary Tract Neoplasms

NCT03982121 2020-02-17

ISILI

Colorectal Cancer Metastatic

NCT04125719 2020-02-11

PPD1

Melanoma

NCT04007588 2020-02-05

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Melanoma

NCT04044651 2020-01-09

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

Phase 2/3 Withdrawn

Hepatitis B, Carcinoma, Hepatocellular

NCT03767439 2019-12-18

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome

NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis

NCT03575234 2019-08-28

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03726281 2019-08-21

Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors

Neoplasms, Germ Cell and Embryonal

NCT03652233 2019-06-20

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT03121417 2019-05-21

Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT03227432 2018-08-14

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Plasma cell

Multiple Myeloma

NCT03149159 2018-06-18

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

Genitourinary

Carcinoma, Renal Cell

NCT03023904 2018-04-25

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Carcinoma, Non-Small-Cell Lung

NCT02962804 2018-03-05

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02736123 2017-09-20

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Melanoma

NCT03283046 2017-09-20

Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Plasma cell

Multiple Myeloma

NCT03149120 2017-08-22

Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT02950038 2017-02-13

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

NCT02400385 2017-02-01

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Melanoma

NCT02357732 2015-12-11

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib